Clinical Trial Update: A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety, immunogenicity, and lot-to-lot consistency of an H5N1 subunit influenza vaccine in adults; results were posted after completion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza

Drugs mentioned

• H5N1 Subunit Influenza Virus Vaccine (Influenza vaccine, H5N1 subunit)

Snippet

Sponsor: Seqirus | Conditions: Avian Influenza | Phase 3 | Status: COMPLETED | Results posted: 2019-04-04